Tate & Lyle Ventures and Agri Investment Fund Invest in Gut-Health Technology Company
This soluble and acid stable ingredient is metabolised by the gut microbiota predominantly in the distal colon, an area of the digestive tract that is vulnerable to disease and often not addressed by other prebiotic fibres.
30/05/08 Tate & Lyle Ventures and Agri Investment Fund have co-led a €3.5m investment into Fugeia, a newly formed functional food technology business with a focus on gut health.
Fugeia is a spin-out company from the Katholieke Universiteit Leuven (K.U. Leuven), whose own Gemma Frisius Fund has co-invested, and the University College Sint-Lieven (KaHo Sint-Lieven). The founders Professor Jan Delcour (Head of the Laboratory of Food Chemistry and Biochemistry of K.U.Leuven) and Professor Willem Broekaert (former Vice President Technology of CropDesign) are joined by a number of eminent advisors from the gut health field: Paul Coussement (Vice President Europe of Metagenics and former CEO of Orafti) joins the board as a non executive director and Professor Glenn Gibson (Head of the Department of Food Sciences, University of Reading) joins the science advisory board, which is chaired by Professor Jan Delcour.
The first product in Fugeia’s pipeline is a proprietary, patent-protected arabinoxylan oligosaccharide ingredient derived from natural wheat bran fibre, with potent prebiotic and antioxidant functionality. This soluble and acid stable ingredient is metabolised by the gut microbiota predominantly in the distal colon, an area of the digestive tract that is vulnerable to disease and often not addressed by other prebiotic fibres.
Simon Barnes of Tate & Lyle Ventures commented: “Gut health is well recognised as a top priority in health and wellness and we believe Fugeia is an ideal commercial platform to develop a range of functional ingredients. It is a privilege for us to have backed such world-renowned individuals in the world of cereal and prebiotics science.”
David Atkinson of Tate & Lyle Ventures added: “Fugeia already has one promising ingredient in the pipeline. With strong clinical data to support its prebiotic effect and robust intellectual property, it is hoped that this product will prove to be a step-changing ingredient in the development of fibre-enhanced foods.”
Luc Basstanie of Agri Investment Fund commented: “Agricultural products have a high intrinsic value and thanks to Fugeia’s technology a range of new ingredients from wheat bran is now available, which can be used in daily food products to benefit human health. Giving agricultural products a higher value in terms of human nutrition is a promising development for the food industry”.
Willem Broekaert, Founder and CEO of Fugeia said: “I am truly excited that Fugeia has been able to complete a highly successful financing round. The strong financial position and backing by a consortium of experienced investors with excellent insight in the food industry puts the company well on track to become a high impact player in gut health technologies.”
Fugeia will be based in Leuven, Belgium.
